Ginkgo Bioworks reported a net loss of $170.3 million for the nine months ended September 30, 2026, an improvement from a $232.0 million loss in the prior year period. Total revenue declined significantly to $67.3 million from $106.7 million year-over-year, while the company reduced operating expenses by approximately $87.3 million through restructuring and lower R&D spending.
Ginkgo Bioworks reported Q3 2026 revenue of $28 million and a GAAP net loss of $41 million, showing improvement from the prior year's $73 million loss. The company highlighted the sale of its first autonomous lab to Novo and new government contracts with ARPA-H and the NSF as it transitions to a platform focused on Autonomous Labs and Cloud Lab services.
Term
Q3 2026
“Ginkgo now has two core offerings built on one autonomous lab platform. This quarter we announced the sale of an autonomous lab to a top-tier pharma company, Novo, alongside new government wins with ARPA-H and the NSF. Our Cloud Lab runs experiments on Nebula, the world's largest autonomous lab, giving pharma an onshore alternative to overseas CROs and giving frontier AI labs a new engine for training data. With the U.S. government now treating autonomous labs as national infrastructure, we believe Ginkgo is well positioned to lead the transition from the bench to autonomous research.”
Jason Kelly, Co-founder and CEO of Ginkgo Bioworks
Ginkgo Bioworks Holdings Insider Reshma P. Shetty Sells $418K of Stock
Reshma P. Shetty sold 41,172 shares of Ginkgo Bioworks Holdings, Inc. at $10.14 a share, worth $418K in total on Oct 19, 2026. Shares held after the trade: 356,329 (-5.0%).
Ginkgo Bioworks Holdings Insider Jason R. Kelly Sells $463K of Stock
Jason R. Kelly sold 45,682 shares of Ginkgo Bioworks Holdings, Inc. at $10.14 a share, worth $463K in total on Oct 19, 2026. Shares held after the trade: 129,065 (-26.1%).